Candida News and Research RSS Feed - Candida News and Research

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

FDA designated Astellas’ isavuconazole as QIDP for treatment of invasive candidiasis

Astellas today announced that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive candidiasis, a life-threatening, invasive fungal infection. [More]
Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas seeks isavuconazole approval from FDA for treatment of life-threatening fungal infections

Astellas today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration seeking approval for isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis), life-threatening fungal infections predominantly occurring in immunocompromised patients. [More]
3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio signs exclusive license agreement with Selecta Biosciences for pegsiticase

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with Selecta Biosciences for pegsiticase (Uricase PEG-20), a pegylated recombinant uricase from candida utilis. [More]
Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Astellas reports efficacy, safety data of isavuconazole invasive aspergillosis SECURE study at ECCMID

Astellas reported today that the efficacy and safety data of the isavuconazole invasive aspergillosis study (SECURE) were presented at the European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain. [More]
Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand's total revenues increase 37% to $16.0 million in first quarter 2014

Ligand Pharmaceuticals Incorporated today reported financial results for the three months ended March 31, 2014, and provided an operating forecast and program updates. [More]
Extremely premature babies should not be given drug to prevent fatal fungal infection

Extremely premature babies should not be given drug to prevent fatal fungal infection

In most circumstances, extremely premature babies should not be given a drug to prevent a potentially fatal fungal infection, according to findings by a Duke Medicine-led research team. [More]
New report provides in-depth analysis and forecast of global market for HAI products

New report provides in-depth analysis and forecast of global market for HAI products

Reportbuyer.com has added a new market research report: Healthcare-Acquired Infection: Devices, Pharmaceuticals, and Environmental Products. [More]
Scientists discover protein structure that helps common fungal pathogen to infect humans

Scientists discover protein structure that helps common fungal pathogen to infect humans

A team that includes scientists from the School of Medicine at The University of Texas Health Science Center at San Antonio, Johns Hopkins University and St. Mary's University reported the structure of a protein that helps a common fungus to infect the body. [More]
Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck's NOXAFIL injection gets FDA approval for intravenous use

Merck, known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration has approved NOXAFIL (posaconazole) injection (18 mg/ mL), a new formulation of NOXAFIL for intravenous (IV) use. [More]
Study shows effect of oral fungal yeast in inhibiting thrush

Study shows effect of oral fungal yeast in inhibiting thrush

Scientists at Case Western Reserve School of Medicine and University Hospitals (UH) Case Medical Center have discovered how the beneficial fungal yeast, Pichia, holds at bay a harmful fungal yeast, Candida. [More]
Bacterium and fungus partner to cause painful form of tooth decay in preschool children

Bacterium and fungus partner to cause painful form of tooth decay in preschool children

Early childhood caries, a highly aggressive and painful form of tooth decay that frequently occurs in preschool children, especially from backgrounds of poverty, may result from a nefarious partnership between a bacterium and a fungus, according to a paper published ahead of print in the journal Infection and Immunity. [More]
Scientists use novel metagenomic approaches to characterize microbial communities that reside in human gut

Scientists use novel metagenomic approaches to characterize microbial communities that reside in human gut

The gut microbiota contains a vast number of microorganisms from all three domains of life, including bacteria, archaea and fungi, as well as viruses. These interact in a complex way to contribute towards both health and the development of disease - interactions that are only now being elucidated thanks to the application of advanced DNA sequencing technology in this field. [More]
Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

Astellas' isavuconazole receives QIDP designation from FDA for zygomycosis treatment

Astellas Pharma Global Development, Inc., a subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the U.S. Food and Drug Administration designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive mucormycosis (also known as zygomycosis), a life-threatening invasive fungal infection caused by certain emerging molds. [More]
Oral garlic tablets shows no effect in clearing vaginal thrush, says study

Oral garlic tablets shows no effect in clearing vaginal thrush, says study

Led by University of Melbourne PhD candidate Cathy Watson also of the Royal Women's Hospital, the findings were published online in the British Journal of Obstetrics and Gynaecology. [More]
Arizona scientists investigate intriguing effects of spaceflight on microbial pathogens

Arizona scientists investigate intriguing effects of spaceflight on microbial pathogens

At Arizona State University's Biodesign Institute, Cheryl Nickerson and her team have been investigating the intriguing effects of spaceflight on microbial pathogens. [More]
Oral garlic does not reduce vaginal thrush, study finds

Oral garlic does not reduce vaginal thrush, study finds

In a world-first study, led by the University of Melbourne and the Royal Women’s Hospital, researchers have found garlic does not significantly reduce vaginal candida (thrush). [More]
IBN and IBM discover new medical application for converted PET bottles

IBN and IBM discover new medical application for converted PET bottles

Researchers at Singapore's Institute of Bioengineering and Nanotechnology (IBN) and California's IBM Research - Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles. [More]
New material effective in destroying drug-resistant fungi

New material effective in destroying drug-resistant fungi

Researchers at Singapore’s Institute of Bioengineering and Nanotechnology (IBN) and California’s IBM Research – Almaden (IBM) have discovered a new, potentially life-saving application for polyethylene terephthalate (PET), which is widely used to make plastic bottles. [More]
FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

FDA grants QIDP status to Astellas' isavuconazole for treatment of invasive aspergillosis

Astellas Pharma US, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, announced today that the U.S. Food and Drug Administration (FDA) designated isavuconazole as a Qualified Infectious Disease Product (QIDP) for the treatment of invasive aspergillosis. [More]
Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck announces approval of NOXAFIL delayed-release tablets by FDA

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved NOXAFIL® (posaconazole) 100 mg delayed-release tablets. [More]